Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Rudin

Showing results (251-260 of 576) with videos related to

Pageof 58
Sort By:
Molecular Cancer Research : MCR|February 1, 2013
Inhibition of TWIST1 leads to activation of oncogene-induced senescence in oncogene-driven non-small cell lung cancerTimothy F Burns, Irina Dobromilskaya, Sara C Murphy, et al.
Future Oncology (London, England)|October 7, 2025
IDeate-Lung02: a Phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancerTaofeek K Owonikoko, Lauren Byers, Ying Cheng, et al.
Molecular Ecology|September 12, 1998
Phylogeography of the West Indian manatee (Trichechus manatus): how many populations and how many taxa?A I Garcia-Rodriguez, B W Bowen, D Domning, et al.
Radiology|July 22, 2016
Lung Adenocarcinoma: Predictive Value of KRAS Mutation Status in Assessing Local Recurrence in Patients Undergoing Image-guided AblationEtay Ziv, Joseph P Erinjeri, Hooman Yarmohammadi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 21, 2004
A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancerJ D Winegarden, A M Mauer, G A Otterson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2004
Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I studyCharles M Rudin, John L Marshall, Chao Hui Huang, et al.
Journal of Hematology & Oncology|June 24, 2023
Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancerCharles M Rudin, Martin Reck, Melissa L Johnson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2016
Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid TumorsValentine M Macaulay, Mark R Middleton, S Gail Eckhardt, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 2, 2014
Clinical characteristics and course of 63 patients with BRAF mutant lung cancersAnya M Litvak, Paul K Paik, Kaitlin M Woo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2003
An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasiaCharles M Rudin, Ezra E W Cohen, Vassiliki A Papadimitrakopoulou, et al.
Pageof 58

Showing results (251-260 of 576) with videos related to

Sort By:
Pageof 58
Molecular Cancer Research : MCR|February 1, 2013
Inhibition of TWIST1 leads to activation of oncogene-induced senescence in oncogene-driven non-small cell lung cancerTimothy F Burns, Irina Dobromilskaya, Sara C Murphy, et al.
Future Oncology (London, England)|October 7, 2025
IDeate-Lung02: a Phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancerTaofeek K Owonikoko, Lauren Byers, Ying Cheng, et al.
Molecular Ecology|September 12, 1998
Phylogeography of the West Indian manatee (Trichechus manatus): how many populations and how many taxa?A I Garcia-Rodriguez, B W Bowen, D Domning, et al.
Radiology|July 22, 2016
Lung Adenocarcinoma: Predictive Value of KRAS Mutation Status in Assessing Local Recurrence in Patients Undergoing Image-guided AblationEtay Ziv, Joseph P Erinjeri, Hooman Yarmohammadi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 21, 2004
A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancerJ D Winegarden, A M Mauer, G A Otterson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2004
Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I studyCharles M Rudin, John L Marshall, Chao Hui Huang, et al.
Journal of Hematology & Oncology|June 24, 2023
Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancerCharles M Rudin, Martin Reck, Melissa L Johnson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2016
Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid TumorsValentine M Macaulay, Mark R Middleton, S Gail Eckhardt, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 2, 2014
Clinical characteristics and course of 63 patients with BRAF mutant lung cancersAnya M Litvak, Paul K Paik, Kaitlin M Woo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2003
An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasiaCharles M Rudin, Ezra E W Cohen, Vassiliki A Papadimitrakopoulou, et al.
Pageof 58